• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

    50.39 -0.87 (-1.70%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 922,203
    Open 51.02
    Bid (Size) 48.27 (1,000)
    Ask (Size) 55.00 (500)
    Prev. Close 51.26
    Today's Range 49.98 - 53.00
    52wk Range 6.710 - 53.65
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗
    a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise... 
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance

    Performance

    YTD
    +26.7%
    +26.7%
    1 Month
    +7.3%
    +7.3%
    3 Month
    +26.9%
    +26.9%
    6 Month
    +116.7%
    +116.7%
    1 Year
    +338.6%
    +338.6%

    More News

    Read More
    News headline image
    Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics to Participate in Four Upcoming Investor Conferences
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
    Via MarketBeat
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Thursday? ↗
    Via Chartmill
    News headline image
    Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗
    Via Benzinga
    News headline image
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗
    Via Investor's Business Daily
    News headline image
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
    From Maze Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
    From Maze Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Maze Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
    Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
    The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
    What is the current price of Maze Therapeutics, Inc. - Common Stock?
    The current price of Maze Therapeutics, Inc. - Common Stock is 50.39
    When was Maze Therapeutics, Inc. - Common Stock last traded?
    The last trade of Maze Therapeutics, Inc. - Common Stock was at 03/17/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.